Parabilis Medicines Reports Q3 2026 Earnings: Revenue of $2. ...
Clinical-Stage Biotech Advances Lead Candidate Toward Phase 3 Registration Related Stocks: PBLS ,
Clinical-Stage Biotech Advances Lead Candidate Toward Phase 3 Registration Related Stocks: PBLS ,